成人霍奇金淋巴瘤的临床特征与转归：来自一家三级医疗机构的经验
Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution.
作者信息
Maddi Rahul Narayan, Linga Vijay Gandhi, Iyer Kalpathi Krishnamani, Chowdary Joseph Stalin, Gundeti Sadashivudu, Digumarti Raghunadharao, Paul Tara Roshini
机构信息
Department of Medical Oncology, Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, Telangana, India.
Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India.
出版信息
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):255-60. doi: 10.4103/0971-5851.171550.
UNLABELLED
Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse.
AIMS
Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities.
SETTINGS AND DESIGN
This is a retrospective analysis from the case records from a single institution.
MATERIALS AND METHODS
Institutional Ethical Committee approval was obtained. Between January 1991 and December 2010, 301 patients (age ≥18 years) underwent treatment at our institution.
STATISTICAL ANALYSIS
Kaplan-Meyer curves were used to calculate the PFS and OS.
RESULTS
The median age at presentation was 36 years, range from 19 to 75 years. The male to female ratio was 2.9:1. Seventy-five percent of patients had B symptoms. Majority presented in advanced stage (Stage III and IV) disease (64.7%). Mixed cellularity (74.4%) was the most common histology, followed by nodular sclerosis (13.9%). The most common chemotherapy regimen used was ABVD (61%).
CONCLUSIONS
Median follow-up of the cohort was 18.5 months (range 2-225). PFS and OS rate at 5 years is 66.3% and 79.7% respectively.
未标注
霍奇金淋巴瘤（HL）的治疗及预后是现代医学真正的成功典范。发展中国家关于HL患者长期预后的数据较为匮乏。
目的
主要目标是评估无进展生存期（PFS）。次要目标是总生存期（OS）和毒性反应。
研究背景与设计
这是一项基于单一机构病例记录的回顾性分析。
材料与方法
获得了机构伦理委员会的批准。1991年1月至2010年12月期间，301例年龄≥18岁的患者在本机构接受了治疗。
统计分析
采用Kaplan-Meier曲线计算PFS和OS。
结果
就诊时的中位年龄为36岁，范围为19至75岁。男女比例为2.9:1。75%的患者有B症状。大多数患者表现为晚期（III期和IV期）疾病（64.7%）。混合细胞型（74.4%）是最常见的组织学类型，其次是结节硬化型（13.9%）。最常用的化疗方案是ABVD（61%）。
结论
该队列的中位随访时间为18.5个月（范围2 - 225个月）。5年时的PFS率和OS率分别为66.3%和79.7%。
Zotero 插件